麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

英國Sense Proteomic  
該公司發(fā)展和應(yīng)用proteomics technology 來研究發(fā)明藥物。發(fā)展和使用protein-related molecular 技術(shù)加強(qiáng)藥物發(fā)明的生產(chǎn)力和加強(qiáng)它的治療效果。

Sense Proteomic is using its functional protein array platform as a powerful new way of discovering disease-specific biomarkers. Autoantibodies are raised when the immune system attacks the body's own proteins in what is classically termed an autoimmune disease. Although many autoimmune diseases such as rheumatoid arthritis, Type I diabetes and lupus have been known for many years, the role of autoantibodies in non-autoimmune diseases has only been recognised more recently.

Specific autoantibodies occur in many diseases including cancer. These autoantibodies are often present years before any clinical manifestation of disease and thus have the potential to be presymptomatic indicators of pathological processes. The identification and characterisation of such autoantibodies in cancer and autoimmune diseases has the potential to enable the development of diagnostic tests with the high sensitivity and specificity necessary for early detection of disease.

Sense Proteomic is using its array technology to identify and quantify the autoantibodies present in patients to identify panels of biomarkers which are indicative of a particular disease. Novel diagnostic tests based on these biomarker panels will be created with the aim to improve the speed and accuracy of disease diagnosis.

By discovering panels of serum autoantibodies, we are defining antibody signatures which will enable:

improvement of disease diagnosis and prognosis
staging of the disease by monitoring the changes in autoantibody production through the disease's progression
monitoring of response to therapeutic interventions
improvement of clinical outcomes by the stratification of patients for clinical trials and treatment.

Sense Proteomic has identified biomarker panels for several diseases including prostate cancer and lupus; other biomarker discovery programs are in progress. If you are interested in partnering with us to discover autoantibody biomarkers for specific diseases, please contact us.